Expansion into a Total Healthcare Company
First written in FY2016. 13 of 25 entries say "Advanced", first in FY2018. Latest entry: 2026-08-06.
FUJIFILM Holdings moved to the "Worse" side of this theme in 2023.
The whole theme swung hardest in 2021: 1 of 7 companies on the "Worse" side.
0 other companies' latest entry also says "Worsened".
- 2026-08-06WorsenedRevisions to earnings forecasts
「The Healthcare segment's consolidated net sales were ¥256.8 billion, up 12.4% year on year. The segment reported an operating loss of ¥12.7 billion.」
The Healthcare segment reported higher sales, while operating performance deteriorated from operating income in the same period of the previous fiscal year to an operating loss. - FY2026AdvancedAnnual report
「As a result, in fiscal 2026 we aim to achieve further revenue growth in the Healthcare segment, exceeding ¥1 trillion in revenue for the third consecutive year after fiscal 2024 and fiscal 2025.」
The Healthcare segment is targeting further revenue growth in fiscal 2026 from revenue of more than ¥1 trillion, following fiscal 2024 and fiscal 2025. Revenue in fiscal 2025 was ¥1,098.9 billion. - FY2026-H1AdvancedAnnual report
「Consolidated revenue for this segment was ¥499,185 million, up 3.1% year on year. Operating income was ¥23,681 million, up 2.8% year on year.」
Healthcare revenue and operating income both exceeded the previous year's levels. In Medical Systems, endoscopes, healthcare IT, and IVD contributed, while in Bio CDMO, the recovery in operations at the Denmark and Texas sites contributed. The disclosure also cites lower demand for medical materials in China and the impact of the stronger yen. - FY2025AchievedAnnual report
「In the Healthcare segment, we will continue to provide products and services using cutting-edge technologies, including our proprietary AI and biotechnology, to address social challenges in healthcare, such as improving QOL (Quality Of Life) in an aging society and developing healthcare infrastructure in emerging countries. As a result, we aim to achieve revenue growth in fiscal 2025, exceeding the ¥1 trillion in Healthcare revenue reached in fiscal 2024.」
Explicitly states that Healthcare revenue reached ¥1 trillion in fiscal 2024 and shifts the target for fiscal 2025 to further revenue growth above that level. - FY2025-H1WorsenedAnnual report
「Consolidated revenue for this segment was ¥472,042 million, up 5.3% year on year. Operating income was ¥22,212 million, down 46.9% year on year.」
Healthcare revenue increased 5.3% year on year, while operating income declined 46.9%, making the coexistence of revenue growth and lower profit seen through the previous fiscal year even more pronounced. - FY2024WorsenedAnnual report
「Operating income in the Healthcare segment decreased by ¥5,392 million from ¥102,770 million in the previous fiscal year due to inventory write-downs and other factors, to ¥97,378 million.」
Healthcare revenue increased 5.0%, while operating income declined 5.2% due to inventory write-downs and other factors. - FY2024RaisedAnnual report
「In the Healthcare segment, we will continue to launch products and services using cutting-edge technologies, including our proprietary AI and biotechnology, to address social challenges in healthcare, such as improving QOL (Quality Of Life) in an aging society and developing healthcare infrastructure in emerging countries. As a result, we aim to achieve revenue growth and higher profit in fiscal 2024, with Healthcare revenue exceeding ¥1 trillion for the first time.」
Sets a more specific, time-bound target for the Healthcare segment: using AI and biotechnology to achieve revenue of more than ¥1 trillion and higher revenue and profit in fiscal 2024. - FY2024-Q3WorsenedAnnual report
「Consolidated revenue for this segment was ¥690,712 million, up 7.6% year on year. Operating income was ¥60,267 million, down 3.2% year on year. In the Medical Systems business, revenue increased as sales of endoscopes, CT/MRI systems, and other products remained strong.」
Healthcare revenue increased through strong sales of endoscopes, CT/MRI systems, and other products, while segment operating income declined 3.2% year on year, with revenue growth and lower profit occurring simultaneously. - FY2024-Q2WorsenedAnnual report
「Consolidated revenue for this segment was ¥448,218 million, up 6.4% year on year. Operating income was ¥41,826 million, down 6.0% year on year.」
Healthcare revenue increased, while operating income declined 6.0% year on year, with revenue growth and lower profit occurring simultaneously. - FY2024-Q1WorsenedAnnual report
「Consolidated revenue for this segment was ¥206,829 million, up 13.1% year on year. Operating income was ¥10,323 million, down 9.1% year on year.」
Healthcare revenue increased, while operating income declined 9.1% year on year. - FY2023RestatedAnnual report
「Operating income in the Healthcare segment decreased by ¥29 million from ¥100,536 million in the previous fiscal year due to higher materials and energy costs, to ¥100,507 million.」
Healthcare revenue increased 14.5%, while operating income was essentially flat year on year due to higher materials and energy costs. - FY2023-Q3WorsenedAnnual report
「Consolidated revenue for this segment was ¥633,777 million, up 9.9% year on year. Operating income was ¥60,627 million, down 19.5% year on year.」
Healthcare revenue increased 9.9% year on year, while operating income declined 19.5%, with revenue growth and lower profit occurring simultaneously. - FY2023-Q2AdvancedAnnual report
「Consolidated revenue for this segment was ¥416,122 million, up 10.8% year on year. Operating income was ¥43,567 million, down 7.3% year on year.」
Healthcare revenue increased 10.8% year on year, while operating income declined 7.3%, with revenue growth and lower profit occurring simultaneously. - FY2022AdvancedAnnual report
「Consolidated revenue in the Healthcare segment increased by ¥222,392 million from ¥579,351 million in the previous fiscal year to ¥801,743 million, driven by higher revenue in the Medical Systems and Bio CDMO businesses, among others. Operating income increased by ¥44,175 million from ¥56,361 million to ¥100,536 million.」
Healthcare revenue increased 38.4% year on year and operating income increased 78.4%, reflecting growth in Medical Systems, Bio CDMO, and other businesses. - FY2022-Q3AdvancedAnnual report
「Consolidated revenue for this segment was ¥576,728 million, up 48.6% year on year. Operating income was ¥75,317 million, up 108.0% year on year.」
Healthcare revenue rose 48.6% and operating income rose 108.0%; collaboration with Fuji Film Healthcare Co., Ltd., which succeeded to Hitachi, Ltd.'s diagnostic imaging-related business, also contributed to the strong results. - FY2022-Q2AdvancedAnnual report
「Consolidated revenue for this segment was ¥375,592 million, up 51.4% year on year. Operating income was ¥47,009 million, up 152.5% year on year.」
Healthcare revenue rose 51.4% and operating income rose 152.5%, indicating that the expansion of the business foundation following the acquisition of the diagnostic imaging-related business is also reflected in performance. - FY2022-Q1AdvancedAnnual report
「In the CT/MRI field, revenue increased due to expanded COVID-19-related demand and the expansion of cross-selling of Fuji Film Healthcare Co., Ltd.'s products through Fuji Film Co., Ltd.'s sales channels, among other factors.」
Following the acquisition of Hitachi, Ltd.'s diagnostic imaging-related business, the Group expanded cross-selling of CT and MRI products through Fuji Film's sales channels, contributing to higher revenue. - FY2021AdvancedAnnual report
「On 31 March 2021, the acquisition of Hitachi, Ltd.'s diagnostic imaging-related business was completed, and Fuji Film Healthcare Co., Ltd., which succeeded to the business, began operations as a new Group company.」
The completion of the acquisition of the diagnostic imaging-related business and the launch of Fuji Film Healthcare Co., Ltd. moved the expansion of the business foundation for the total healthcare vision into the implementation phase. - FY2020AdvancedAnnual report
「We will build a strong business foundation for further growth in the Medical Systems business by maximizing synergies with the diagnostic imaging-related business to be acquired from Hitachi, Ltd.」
Specifically describes plans to maximize synergies after acquiring Hitachi, Ltd.'s diagnostic imaging-related business and strengthen the Medical Systems business foundation. - FY2020-Q3AdvancedAnnual report
「In December 2019, we announced the acquisition of Hitachi, Ltd.'s diagnostic imaging-related business. Through this acquisition, we will provide a broader range of higher-quality solutions, play an advanced role in improving the quality of healthcare, and establish a business foundation as one of the world's leading healthcare companies. Completion of the acquisition is scheduled for July 2020, subject to obtaining clearance from the relevant competition authorities and satisfying other conditions. This transaction will have no impact on consolidated results for fiscal 2019.」
The announcement of the acquisition of the diagnostic imaging-related business gives concrete form to plans to further expand the range of healthcare solutions and the healthcare business foundation. Completion of the acquisition is scheduled for July 2020. - FY2020-Q1AdvancedAnnual report
「In May 2019, we announced the acquisition of medwork, a company engaged in the development, manufacture, and sale of endoscopic treatment devices, marking our full-scale entry into the endoscopic treatment device business.」
Shows plans to expand the scope of the total healthcare business from endoscopes and related products to the development, manufacture, and sale of endoscopic treatment devices. - FY2018AdvancedAnnual report
「In the Medical Systems business, we will strengthen proposals for comprehensive solutions centered on highly competitive healthcare IT, leveraging a broad lineup based on image-processing technology, including X-ray imaging diagnostic equipment, healthcare IT, endoscopy, ultrasound, and IVD.」
Gives concrete form to the total healthcare vision through comprehensive solutions combining healthcare IT, X-ray, endoscopy, ultrasound, and IVD to cover prevention, diagnosis, and treatment. - FY2016First statedAnnual report
「The Group is expanding its business with the aim of becoming a total healthcare company covering the fields of prevention, diagnosis, and treatment.」
Presents a business vision covering the 3 fields of prevention, diagnosis, and treatment.